Olanzapine
Aanvraaginformatie
| Omschrijving: | Olanzapine |
| Synoniemen: | Zyprexa |
| Aanvraagcode: | AA86 |
| Uitvoerend Lab: | KFTL |
| Aanvraagformulier: | DZ-Klinisch Farmaceutisch en Toxicologisch onderzoek |
| Benodigde Informatie: | dosering, tijd inname, tijd afname, comedicatie |
| CITO Aanvraagbaar: | Ja |
| Contactpersoon: | I. van Berlo |
| Opmerkingen: |
Materiaal afname/opslag
| Materiaal: | Apotheek serum (GEEN gel) |
| Alternatief Materiaal: | |
| Afname Volume: | 4 ml |
| Minimaal nodig: | 0.5 ml serum |
| Afnameconditie: | 10-24 uur na inname |
| Bewaarcondities: | -20 °C |
| Bewaarperiode: | 14 dagen |
| Verzendformulier: | |
| Verzendcondities: | nvt |
Interpretatie
| Indicatie: | pyschose, bipolaire stoornis |
| Eenheid: | µg/l |
| Referentiewaarden: | 20-80 µg/l |
| Interpretatie: | - Psychose: 20-80 microgram/L
- Anorexia: 10-40 microgram/L
- Toxisch: > 100 microgram/L
Er zijn aanwijzingen dat spiegels > 40 ug/l niet meer bijdragen aan de effectiviteit.
Bij de interpretatie van de resultaten dient rekening gehouden te worden met de meetonzekerheid van de analysemethode. Deze meetonzekerheid is op te vragen bij de ziekenhuisapotheker laboratorium. |
| Testeigenschappen: | ISO15189 M272 KF.TDM.02 |
| Doorbelgrenzen: | Olanzapine > 100 ug/l |
| Bronvermelding: | -Hiemke et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. pharmacospychiatry 44:195-235 -Weigmann H , Härtter S , Maehrlein S et al. Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography J Chromatogr B Biomed Sci Appl 2001 ; 759 : 63 – 71 -Skogh E , Reis M , Dahl M L et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting . Ther Drug Monit 2002 ; 24 : 518 – 526 -Perry P J , Sanger T , Beasley C . Olanzapine plasma concentrations and clinical response in acutely III schizophrenic patients . J Clin Psychopharmacol 1997 ; 17 : 472 – 477 -Nozawa M , Ohnuma T , Matsubara Y et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics . Ther Drug Monit 2008 ; 30 : 35 – 40 -Mamo D , Kapur S , Keshavan M et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia . Neuropsychopharmacology 2008 ; 33 : 298 – 304 -Gex-Fabry M , Balant-Gorgia A E , Balant L P . Therapeutic drug monitoring of olanzapine: the combined eff ect of age, gender, smoking, and comedication . Ther Drug Monit 2003 ; 25 : 46 – 53 -Feng Y , Pollock B G , Coley K et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study . J Clin Pharmacol 2008 ; 66 : 629 – 639 -Citrome L , Stauff er V L , Chen L et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia . J Clin Psychopharmacol 2009 ; 29 : 278 – 283 -Bergemann N , Frick A , Parzer P et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients . Pharmacopsychiatry 2004 ; 37 : 63 – 68 -Bech P , Gex-Fabry M , Aubry J M et al. Olanzapine plasma level in relation to antimanic eff ect in the acute therapy of manic states . Nord J Psychiatry 2006 ; 60 : 181 – 182 -Bachmann C J , Haberhausen M , Heinzel-Gutenbrunner M et al. Large intraindividual variability of olanzapine serum concentrations in adolescent patients . Ther Drug Monit 2008 ; 30 : 108 – 112
|
Testeigenschappen
| Methode: | LC-MSMS |
| Analyse Frequentie: | wekelijks dinsdag |
| Doorlooptijd: | 9 dagen |
| CTG-Klasse: | |
| Tarief: | |
| LIS Code: | AA86 |